DE22817174T1 - Konjugate mit einem phosphor (v) und einem wirkstoffteil - Google Patents
Konjugate mit einem phosphor (v) und einem wirkstoffteil Download PDFInfo
- Publication number
- DE22817174T1 DE22817174T1 DE22817174.0T DE22817174T DE22817174T1 DE 22817174 T1 DE22817174 T1 DE 22817174T1 DE 22817174 T DE22817174 T DE 22817174T DE 22817174 T1 DE22817174 T1 DE 22817174T1
- Authority
- DE
- Germany
- Prior art keywords
- conjugate
- optionally substituted
- alkyl
- range
- bond
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
- C07F9/4461—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4476—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aromatic amines (N-C aromatic linkage)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21207195 | 2021-11-09 | ||
| EP21207195 | 2021-11-09 | ||
| PCT/EP2022/081345 WO2023083900A1 (en) | 2021-11-09 | 2022-11-09 | Conjugates comprising a phosphorus (v) and a drug moiety |
| EP22817174.0A EP4429708A1 (en) | 2021-11-09 | 2022-11-09 | Conjugates comprising a phosphorus (v) and a drug moiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE22817174T1 true DE22817174T1 (de) | 2024-12-12 |
Family
ID=78592631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE22817174.0T Pending DE22817174T1 (de) | 2021-11-09 | 2022-11-09 | Konjugate mit einem phosphor (v) und einem wirkstoffteil |
Country Status (15)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL321506A (en) * | 2022-12-22 | 2025-08-01 | Tubulis Gmbh | Conjugates comprising a phosphorus(v) moiety and a drug |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| KR20260065883A (ko) | 2023-09-01 | 2026-05-11 | 투불리스 게엠베하 | 포스포나미데이트 화합물의 제조 방법 |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗il-1rap結合結構域及其抗體-藥物偶聯物 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US12521446B2 (en) | 2024-02-27 | 2026-01-13 | Bristol-Myers Squibb Company | Anti-CEACAM5 antibody drug conjugates |
| WO2025262641A1 (en) | 2024-06-19 | 2025-12-26 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
| WO2026096695A1 (en) | 2024-10-31 | 2026-05-07 | Bristol-Myers Squibb Company | Anti-fucosyl-gm1 antibody drug conjugates |
| WO2026107136A1 (en) | 2024-11-14 | 2026-05-21 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates for the treatment of cancer |
| WO2026105061A1 (en) | 2024-11-15 | 2026-05-21 | Pheon Therapeutics Ltd | Antibody-drug conjugates that bind cdcp1 and uses thereof |
| US20260144885A1 (en) | 2024-11-22 | 2026-05-28 | Bristol-Myers Squibb Company | Anti-lrrc15 antibodies and uses thereof |
| US20260144884A1 (en) | 2024-11-22 | 2026-05-28 | Bristol-Myers Squibb Company | Anti-lrrc15 antibody drug conjugates |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US633410A (en) | 1898-09-22 | 1899-09-19 | George A Ames | Ice-cutter. |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| JP2763020B2 (ja) | 1995-04-27 | 1998-06-11 | 日本電気株式会社 | 半導体パッケージ及び半導体装置 |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| EP1731174A3 (en) | 1996-08-02 | 2007-01-17 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| NZ588884A (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Cross-linkers and their uses |
| PT3057585T (pt) | 2013-10-15 | 2020-10-21 | Seagen Inc | Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando |
| WO2018041985A1 (en) | 2016-09-01 | 2018-03-08 | Forschungsverbund Berlin E.V. | Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates |
| US12453779B2 (en) | 2018-03-07 | 2025-10-28 | Forschungsverbund Berlin E.V. | Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates |
| TWI920652B (zh) | 2018-06-07 | 2026-04-01 | 美商思進公司 | 喜樹鹼結合物 |
-
2022
- 2022-11-09 US US18/054,018 patent/US20230330258A1/en not_active Abandoned
- 2022-11-09 ES ES22817174T patent/ES2999335T1/es active Pending
- 2022-11-09 CA CA3237371A patent/CA3237371A1/en active Pending
- 2022-11-09 JP JP2024549576A patent/JP2024540691A/ja active Pending
- 2022-11-09 IL IL312675A patent/IL312675A/en unknown
- 2022-11-09 PE PE2024001005A patent/PE20242107A1/es unknown
- 2022-11-09 KR KR1020247019065A patent/KR20240100413A/ko active Pending
- 2022-11-09 MX MX2024005546A patent/MX2024005546A/es unknown
- 2022-11-09 WO PCT/EP2022/081345 patent/WO2023083900A1/en not_active Ceased
- 2022-11-09 EP EP22817174.0A patent/EP4429708A1/en active Pending
- 2022-11-09 AU AU2022385379A patent/AU2022385379A1/en active Pending
- 2022-11-09 DE DE22817174.0T patent/DE22817174T1/de active Pending
- 2022-11-09 CN CN202280074835.4A patent/CN118302197A/zh active Pending
-
2024
- 2024-05-06 CL CL2024001372A patent/CL2024001372A1/es unknown
- 2024-05-06 CO CONC2024/0005877A patent/CO2024005877A2/es unknown
-
2025
- 2025-05-14 US US19/207,970 patent/US20250281634A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022385379A1 (en) | 2024-06-20 |
| US20250281634A1 (en) | 2025-09-11 |
| CO2024005877A2 (es) | 2024-07-08 |
| KR20240100413A (ko) | 2024-07-01 |
| CA3237371A1 (en) | 2023-05-19 |
| CN118302197A (zh) | 2024-07-05 |
| ES2999335T1 (en) | 2025-02-25 |
| CL2024001372A1 (es) | 2024-10-25 |
| JP2024540691A (ja) | 2024-10-31 |
| EP4429708A1 (en) | 2024-09-18 |
| MX2024005546A (es) | 2024-07-10 |
| IL312675A (en) | 2024-07-01 |
| US20230330258A1 (en) | 2023-10-19 |
| WO2023083900A1 (en) | 2023-05-19 |
| PE20242107A1 (es) | 2024-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE22817180T1 (de) | Konjugate mit einem phosphor (v) und einem camptothecinteil | |
| DE3788058T2 (de) | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. | |
| JP2024540691A5 (cg-RX-API-DMAC7.html) | ||
| DE69622157T2 (de) | Zusammensetzung zur verhinderung von osteolyse und metastasen | |
| DE69830591T2 (de) | HEILUNG VON BRUCHVERLETZUNGEN UNTER VERWENDUNG VON PTHrP ANALOGEN | |
| DE69925830T2 (de) | Peg-lhrh analog konjugate | |
| US20240173427A1 (en) | Glypican 3 antibodies and conjugates thereof | |
| DE69831224T2 (de) | Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen | |
| DE69333182T2 (de) | Therapeutische konjugate von toxinen und medikamenten | |
| DE69027121T2 (de) | Bindeligande für tumornekrosisfaktor | |
| ES2999335T1 (en) | Conjugates comprising a phosphorus (v) and a drug moiety | |
| DE68912334T2 (de) | Immunokonjugate für krebs-diagnose und -therapie. | |
| DE69616114T2 (de) | Folien zur Hemmung der Adhäsion und Zusammensetzungen für medizinische Zwecke | |
| DE68921982T2 (de) | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. | |
| DE68928667T2 (de) | Peptide als arzneimittel | |
| EP0305967B1 (de) | Konjugate von Interferon alpha mit Immunglobulinen | |
| DE60032926T2 (de) | Verbesserung von peptid-transport durch konjugation mit gallensäuren | |
| DE69029184T2 (de) | Hydrophile Derivate, diagnostische und therapeutische Anwendungen, diagnostische oder therapeutische Reagenziensätze und immunologische Reagenzien | |
| DE10355251A1 (de) | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor | |
| DE69625354T2 (de) | Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen | |
| DE3650032T2 (de) | Anticytomegaloviraler menschlicher monoklonaler antikörper und dessen herstellung. | |
| CN107683146A (zh) | 位点特异性抗体‑药物缀合物 | |
| EP0538754A2 (de) | Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression | |
| Coonrad et al. | Trapping of the posterior tibial tendon and interposition of soft tissue in severe fractures about the ankle joint | |
| EP0346501A1 (de) | Arzneimittelzubereitung zur behandlung des immunmangels |